THOUSAND OAKS, California—Amgen is currently enrolling patients in a phase III study designed to evaluate the effectiveness of panitumumab (Vectibix) in combination with chemotherapy (FOLFIRI), compared with FOLFIRI alone as second-line chemotherapy in patients with previously treated metastatic colorectal cancer.
Vectibix is a fully human anti-EGFR monoclonal antibody. It was FDA approved in 2006 for third-line treatment of metastatic colorectal cancer with disease progression on or following chemotherapy regimens based on fluoropyrimidine, oxaliplatin(Drug information on oxaliplatin) (Eloxatin), or irinotecan(Drug information on irinotecan) (Camptosar). The approval was based on improved progression-free survival data.
The study is open to men and women whose metastatic disease has progressed while on or following treatment with a standard first-line chemotherapy regimen that includes 5-fluorouracil. Patients must have ECOG performance status of 0-2, radiologically documented disease progression, at least one measurable lesion of at least 20 mm, no prior irinotecan therapy, and no prior anti-EGFR therapy.
Physicians or patients interested in exploring study participation can log on to www.AmgenTrials.com or call 1-800-772-6436 (1-800-77-AMGEN).
